<br>        Primary Inclusion Criteria:<br><br>          -  Current diagnosis of alcohol dependence, meeting at least 5 of DSM-IV criteria<br><br>          -  Expected to complete inpatient treatment for alcohol dependence within 24 hours of<br>             randomization<br><br>          -  Must have 7-21 days, inclusive, of inpatient treatment for alcohol dependence prior to<br>             first dose<br><br>          -  Negative urine toxicological screen for opioids on the day of randomization<br><br>          -  Women of childbearing potential must agree to use an approved method of contraception<br>             for the study duration<br><br>        Primary Exclusion Criteria:<br><br>          -  Pregnancy or lactation<br><br>          -  Evidence of hepatic failure including: ascites, bilirubin >10% above upper limit of<br>             normal and/or esophageal variceal disease<br><br>          -  Current dependence (within the past year) to benzodiazepines, opioids or cocaine by<br>             DSM-IV criteria<br><br>          -  Use of any opioids and/or methadone within 14 days prior to the screening visit, or<br>             subjects likely to require opioid therapy during the study period<br><br>          -  Use of oral naltrexone, acamprosate, or disulfiram within 14 days prior to screening<br><br>          -  Known intolerance and/or hypersensitivity to naltrexone, carboxymethylcellulose, or<br>             PLG<br><br>          -  Parole, probation, or pending legal proceedings having the potential for incarceration<br>             during the study period<br>      ;<br>        Primary Inclusion Criteria:<br><br>          -  Current diagnosis of alcohol dependence, meeting at least 5 of DSM-IV criteria<br><br>          -  Expected to complete inpatient treatment for alcohol dependence within 24 hours of<br>             randomization<br><br>          -  Must have 7-21 days, inclusive, of inpatient treatment for alcohol dependence prior to<br>             first dose<br><br>          -  Negative urine toxicological screen for opioids on the day of randomization<br><br>          -  Women of childbearing potential must agree to use an approved method of contraception<br>             for the study duration<br><br>        Primary Exclusion Criteria:<br><br>          -  Pregnancy or lactation<br><br>          -  Evidence of hepatic failure including: ascites, bilirubin >10% above upper limit of<br>             normal and/or esophageal variceal disease<br><br>          -  Current dependence (within the past year) to benzodiazepines, opioids or cocaine by<br>             DSM-IV criteria<br><br>          -  Use of any opioids and/or methadone within 14 days prior to the screening visit, or<br>             subjects likely to require opioid therapy during the study period<br><br>          -  Use of oral naltrexone, acamprosate, or disulfiram within 14 days prior to screening<br><br>          -  Known intolerance and/or hypersensitivity to naltrexone, carboxymethylcellulose, or<br>             PLG<br><br>          -  Parole, probation, or pending legal proceedings having the potential for incarceration<br>             during the study period<br>      ;<br>        Primary Inclusion Criteria:<br><br>          -  Current diagnosis of alcohol dependence, meeting at least 5 of DSM-IV criteria<br><br>          -  Expected to complete inpatient treatment for alcohol dependence within 24 hours of<br>             randomization<br><br>          -  Must have 7-21 days, inclusive, of inpatient treatment for alcohol dependence prior to<br>             first dose<br><br>          -  Negative urine toxicological screen for opioids on the day of randomization<br><br>          -  Women of childbearing potential must agree to use an approved method of contraception<br>             for the study duration<br><br>        Primary Exclusion Criteria:<br><br>          -  Pregnancy or lactation<br><br>          -  Evidence of hepatic failure including: ascites, bilirubin >10% above upper limit of<br>             normal and/or esophageal variceal disease<br><br>          -  Current dependence (within the past year) to benzodiazepines, opioids or cocaine by<br>             DSM-IV criteria<br><br>          -  Use of any opioids and/or methadone within 14 days prior to the screening visit, or<br>             subjects likely to require opioid therapy during the study period<br><br>          -  Use of oral naltrexone, acamprosate, or disulfiram within 14 days prior to screening<br><br>          -  Known intolerance and/or hypersensitivity to naltrexone, carboxymethylcellulose, or<br>             PLG<br><br>          -  Parole, probation, or pending legal proceedings having the potential for incarceration<br>             during the study period<br>      ;<br>        Primary Inclusion Criteria:<br><br>          -  Current diagnosis of alcohol dependence, meeting at least 5 of DSM-IV criteria<br><br>          -  Expected to complete inpatient treatment for alcohol dependence within 24 hours of<br>             randomization<br><br>          -  Must have 7-21 days, inclusive, of inpatient treatment for alcohol dependence prior to<br>             first dose<br><br>          -  Negative urine toxicological screen for opioids on the day of randomization<br><br>          -  Women of childbearing potential must agree to use an approved method of contraception<br>             for the study duration<br><br>        Primary Exclusion Criteria:<br><br>          -  Pregnancy or lactation<br><br>          -  Evidence of hepatic failure including: ascites, bilirubin >10% above upper limit of<br>             normal and/or esophageal variceal disease<br><br>          -  Current dependence (within the past year) to benzodiazepines, opioids or cocaine by<br>             DSM-IV criteria<br><br>          -  Use of any opioids and/or methadone within 14 days prior to the screening visit, or<br>             subjects likely to require opioid therapy during the study period<br><br>          -  Use of oral naltrexone, acamprosate, or disulfiram within 14 days prior to screening<br><br>          -  Known intolerance and/or hypersensitivity to naltrexone, carboxymethylcellulose, or<br>             PLG<br><br>          -  Parole, probation, or pending legal proceedings having the potential for incarceration<br>             during the study period<br>